https://www.tgtherapeutics.com/publications/phase-i-ii-study-of-umbralisib-tgr-1202-ublituximab-tg-1101-and-pembrolizumab-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-and-richters-transformation-5-year-fo/ 2025-01-29T17:55:34+00:00 https://www.tgtherapeutics.com/publications/a-phase-i-trial-of-tgr-1202-a-next-generation-once-daily-pi3k-delta-inhibitor-in-combination-with-obinutuzumab-plus-chlorambucil-in-patients-with-chronic-lymphocytic-leukemia/ 2025-01-30T18:45:48+00:00 https://www.tgtherapeutics.com/publications/a-novel-once-daily-pi3k-delta-inhibitor-demonstrates-clinical-activity-with-a-favorable-differentiated-safety-profile-as-a-single-agent-and-in-combination-with-a-novel-glyocengineered-anti-cd20-mab/ 2025-01-30T19:16:50+00:00 https://www.tgtherapeutics.com/publications/a-phase-i-study-of-lfb-r603-a-novel-anti-cd20-antibody-in-patients-with-relapsed-chronic-lymphocytic-leukemia/ 2025-01-31T22:06:37+00:00 https://www.tgtherapeutics.com/publications/tg20-a-transgenically-derived-anti-cd20-monoclonal-antibody-exhibits-enhanced-cytotoxicity-against-cells-with-low-levels-of-cd20/ 2025-01-31T22:06:58+00:00 https://www.tgtherapeutics.com/publications/multicentre-phase-i-study-with-an-8-dose-regimen-of-single-agent-anti-cd20-monoclonal-antibody-lfb-r603-in-patients-with-relapsed-chronic-lymphocytic-leukemia-cll/ 2025-01-31T22:07:13+00:00 https://www.tgtherapeutics.com/publications/comparison-of-cell-lysis-mediated-by-lfb-r603-with-that-mediated-by-ofatumumab-against-cells-expressing-low-levels-of-cd20/ 2025-01-31T22:07:46+00:00 https://www.tgtherapeutics.com/publications/inhibition-of-pi3kd-kinase-by-a-selective-small-molecule-inhibitor-suppresses-b-cell-proliferation-and-leukemic-cell-growth/ 2025-01-31T22:08:06+00:00 https://www.tgtherapeutics.com/publications/ublituximab-an-optimized-anti-cd20-monoclonal-antibody-demonstrates-greater-nk-mediated-adcc-than-rituximab-in-waldenstroms-macroglobulinemia-patients-supporting-a-therapeutic-strategy-with-ublitu/ 2025-01-31T22:08:28+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tgtx-1101-a-novel-third-generation-anti-cd20-antibody-demonstrates-enhanced-antitumor-activity-compared-to-rituximab-in-primary-cns-and-intraocular-lymphoma-murine-models/ 2025-01-31T22:08:43+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tgtx-1101-a-novel-anti-cd20-monoclonal-antibody-mab-demonstrates-activity-in-rituximab-sensitive-and-rituximab-resistant-b-non-hodgkin-lymphoma-b-nhl-pre-clinical-in-vitro/ 2025-01-31T22:08:57+00:00 https://www.tgtherapeutics.com/publications/tgr-1202-suppresses-aml-and-all-cells-via-selective-inhibition-of-pi3k-delta-kinase/ 2025-01-31T22:09:21+00:00 https://www.tgtherapeutics.com/publications/novel-pi3k-inhibitors-demonstrate-marked-cytotoxicity-in-models-of-t-cell-lymphoma-caused-apoptosis-and-were-synergistic-with-the-novel-anti-cd20-monoclonal-antibody-ublituximab-in-models-of-b-cell-2/ 2025-01-31T22:09:36+00:00 https://www.tgtherapeutics.com/publications/comparison-of-the-pi3k-delta-inhibitors-tgr1202-and-gs-1101-in-inducing-cytotoxicity-and-inhibiting-phosphorylation-of-akt-in-cll-cells-in-vitro/ 2025-01-31T22:09:55+00:00 https://www.tgtherapeutics.com/publications/combined-carfilzomib-and-selective-pi3k-d-inhibition-tgr-1202-results-in-enhanced-myeloma-cell-apoptosis/ 2025-01-31T22:10:21+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tg-1101-a-novel-anti-cd20-monoclonal-for-rituximab-relapsed-refractory-b-cell-malignancies/ 2025-01-31T22:10:46+00:00 https://www.tgtherapeutics.com/publications/a-novel-pi3k-delta-specific-inhibitor-in-multiple-myeloma/ 2025-01-31T22:11:01+00:00 https://www.tgtherapeutics.com/publications/final-results-of-a-multicenter-phase-ib-single-agent-study-with-the-novel-anti-cd20-monoclonal-antibody-ublituximab-tg-1101-in-patients-with-relapsed-chronic-lymphocytic-leukemia-cll/ 2025-01-31T22:11:15+00:00 https://www.tgtherapeutics.com/publications/a-phase-i-dose-escalation-trial-of-ublituximab-tg-1101-a-novel-anti-cd20-monoclonal-antibody-mab-for-rituximab-relapsed-and-or-refractory-c-cell-lymphoma-patients/ 2025-01-31T22:11:30+00:00 https://www.tgtherapeutics.com/publications/novel-pi3k-inhibitors-demonstrate-marked-cytotoxicity-in-models-of-t-cell-lymphoma-caused-apoptosis-and-were-synergistic-with-the-novel-anti-cd20-monoclonal-antibody-ublituximab-in-models-of-b-cell-l/ 2025-01-31T22:11:53+00:00 https://www.tgtherapeutics.com/publications/the-pi3k-delta-inhibitor-tgr-1202-induces-cytotoxicity-and-inhibits-phosphorylation-of-akt-in-17p-deleted-and-non-17p-deleted-cll-cells-in-vitro-2/ 2025-01-31T22:12:16+00:00 https://www.tgtherapeutics.com/publications/the-pi3k-d-inhibitor-tgr-1202-in-combination-with-brentuximab-vedotin-sgn-35-synergistically-induces-g2-m-phase-arrest-and-cell-death-via-inhibition-of-tubulin-polymerization-in-hodgkin-lymphoma-cel/ 2025-01-31T22:12:40+00:00 https://www.tgtherapeutics.com/publications/the-pi3k-delta-inhibitor-tgr-1202-and-proteasome-inhibitor-carfilzomib-are-highly-synergistic-in-killing-human-b-and-t-cell-lymphoma-cells/ 2025-01-31T22:12:56+00:00 https://www.tgtherapeutics.com/publications/a-phase-i-dose-escalation-study-of-tgr-1202-a-novel-pi3k-d-inhibitor-for-patients-with-relapsed-or-refractory-hematologic-malignancies/ 2025-01-31T22:13:10+00:00 https://www.tgtherapeutics.com/publications/the-pi3k-delta-inhibitor-tgr-1202-induces-cytotoxicity-and-inhibits-phosphorylation-of-akt-in-17p-deleted-and-non-17p-deleted-cll-cells-in-vitro/ 2025-01-31T22:13:28+00:00 https://www.tgtherapeutics.com/publications/the-pi3k-delta-inhibitor-tgr-1202-in-combination-with-brentuximab-vedotin-sgn-35-synergistically-induces-g2-m-phase-arrest-and-cell-death-via-inhibition-of-tubulin-polymerization-in-hodgkin-lymphoma/ 2025-01-31T22:13:42+00:00 https://www.tgtherapeutics.com/publications/activity-of-tgr-1202-a-novel-once-daily-pi3k-delta-inhibitor-in-patients-with-relapsed-or-refractory-hematologic-malignancies-2/ 2025-01-31T22:14:09+00:00 https://www.tgtherapeutics.com/publications/a-phase-i-trial-of-ublituximab-tg-1101-a-novel-anti-cd20-monoclonal-antibody-mab-in-b-cell-lymphoma-patients-with-prior-exposure-to-rituximab/ 2025-01-31T22:14:21+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tg-1101-a-novel-glycoenginereed-anti-cd20-mab-in-combination-with-ibrutinib-in-patients-with-cll-and-mcl-results-of-an-ongoing-phase-ii-trial/ 2025-01-31T22:14:42+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tg-1101-a-novel-anti-cd20-monoclonal-antibody-for-rituximab-relapsed-refractory-b-cell-malignancies/ 2025-01-31T22:14:57+00:00 https://www.tgtherapeutics.com/publications/activity-of-tgr-1202-a-novel-once-daily-pi3k-delta-inhibitor-in-patients-with-relapsed-or-refractory-hematologic-malignancies/ 2025-01-31T22:15:15+00:00 https://www.tgtherapeutics.com/publications/a-phase-i-trial-of-ublituximab-a-novel-glycoengineered-anti-cd20-mab-in-combination-with-tgr-1202-a-next-generation-pi3k-delta-inhibitor-in-patients-with-chronic-lymphocytic-leukemia-and-non-hodgk/ 2025-01-31T22:15:35+00:00 https://www.tgtherapeutics.com/publications/ublituximab-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-combination-with-tgr-1202-a-next-generation-once-daily-pi3k-delta-inhibitor-demonstrate-activity-in-heavily-pre-treated-a/ 2025-01-31T22:16:01+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tg-1101-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-in-combination-with-ibrutinib-is-highly-active-in-patients-with-relapsed-and-or-refractory-cll-and-mcl-results-of-a-phase/ 2025-01-31T22:16:14+00:00 https://www.tgtherapeutics.com/publications/the-pi3k-delta-inhibitor-tgr-1202-in-combination-with-brentuximab-vedotin-sgn-35-synergistically-inhibits-tubulin-polymerization-and-exerts-potent-antitumor-effects-in-nod-scid-mice-with-hodgkin-lym/ 2025-01-31T22:16:28+00:00 https://www.tgtherapeutics.com/publications/tgr-1202-a-novel-once-daily-pi3k-delta-inhibitor-demonstrates-clinical-activity-with-a-favorable-safety-profile-lacking-hepatotoxicity-in-patients-with-chronic-lymphocytic-leukemia-and-b-cell-lymp/ 2025-01-31T22:16:43+00:00 https://www.tgtherapeutics.com/publications/complementary-targeting-of-pi3k-and-the-proteasome-causes-potent-inhibition-of-mtorc1-and-nf-kappab-in-models-of-b-and-t-cell-lymphoma/ 2025-01-31T22:16:56+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tgr-1202-demonstrates-activity-and-a-favorable-safety-profile-in-relapsed-refractory-b-cell-nhl-and-high-risk-cll-phase-i-results/ 2025-01-31T22:17:17+00:00 https://www.tgtherapeutics.com/publications/irak4-inhibitors-display-synergistic-activity-when-combined-with-btk-or-pi3k-inhibitors-in-b-cell-lymphomas/ 2025-01-31T22:17:35+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tgr-1202-demonstrates-activity-and-favorable-safety-profile-in-relapsed-refractory-b-cell-nhl-and-high-risk-cll-2/ 2025-01-31T22:17:59+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tg-1101-a-novel-glycoengineered-anti-cd20-mab-in-combination-with-ibrutinib-achieves-95-orr-in-patients-with-high-risk-relapsed-refractory-cll/ 2025-01-31T22:18:11+00:00 https://www.tgtherapeutics.com/publications/safety-and-activity-of-the-chemotherapy-free-triplet-of-ublituximab-tgr-1202-and-ibrutinib-is-safe-and-highly-active-in-relapsed-b-cell-malignancies/ 2025-01-31T22:18:24+00:00 https://www.tgtherapeutics.com/publications/clinical-activity-and-safety-profile-of-tgr-1202-a-novel-once-daily-pi3k-delta-inhibitor-demonstrates-clinical-activity-with-a-favorable-safety-profile-lacking-hepatotoxicity-in-patients-with-cll-a-2/ 2025-01-31T22:18:38+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tgr-1202-demonstrates-activity-and-favorable-safety-profile-in-relapsed-refractory-b-cell-nhl-and-high-risk-cll/ 2025-01-31T22:18:52+00:00 https://www.tgtherapeutics.com/publications/clinical-activity-and-safety-profile-of-tgr-1202-a-novel-once-daily-pi3k-delta-inhibitor-demonstrates-clinical-activity-with-a-favorable-safety-profile-lacking-hepatotoxicity-in-patients-with-cll-a/ 2025-01-31T22:19:06+00:00 https://www.tgtherapeutics.com/publications/ubliuximab-tgr-1202-demonstrates-activity-and-favorable-safety-profile-in-relapsed-refractory-b-cell-nhl-and-high-risk-cll/ 2025-01-31T22:19:19+00:00 https://www.tgtherapeutics.com/publications/safety-and-activity-of-the-chemotherapy-free-triplet-of-ublituximab-tgr-1202-and-ibrutinib-in-relapsed-b-cell-malignancies/ 2025-01-31T22:19:35+00:00 https://www.tgtherapeutics.com/publications/clinical-activity-and-safety-profile-of-tgr-1202-a-novel-once-daily-pi3k-delta-inhibitor-in-patients-with-cll-and-b-cell-lymphoma-2/ 2025-01-31T22:22:12+00:00 https://www.tgtherapeutics.com/publications/disruption-of-the-mtor-eif4f-axis-by-selectively-targeting-pi3kdelta-and-proteasome-potently-inhibits-cap-dependent-translation-of-c-myc-in-aggressive-lymphomas/ 2025-01-31T22:24:32+00:00 https://www.tgtherapeutics.com/publications/clinical-activity-and-safety-profile-of-tgr-1202-a-novel-once-daily-pi3k-delta-inhibitor-in-patients-with-cll-and-b-cell-lymphoma/ 2025-01-31T22:24:55+00:00 https://www.tgtherapeutics.com/publications/differential-regulation-of-human-t-cells-by-tgr-1202-a-novel-pi3k-delta-inhibitor/ 2025-01-31T22:26:46+00:00 https://www.tgtherapeutics.com/publications/long-term-follow-up-of-the-pi3k-delta-inhibitor-tgr-1202-demonstrates-a-differentiated-safety-profile-and-high-response-rates-in-cll-and-nhl-integrated-analysis-of-tgr-1202-monotherapy-and-combined-w/ 2025-01-31T22:27:09+00:00 https://www.tgtherapeutics.com/publications/preliminary-results-of-a-phase-i-ib-study-of-ibrutinib-in-combination-with-tgr-1202-in-patients-with-relapsed-refractory-cll-or-mcl/ 2025-01-31T22:27:22+00:00 https://www.tgtherapeutics.com/publications/long-term-follow-up-of-pi3k-delta-inhibitor-tgr-1202-demonstrates-safety-and-high-response-rates-in-nhl-integrated-analysis-of-tgr-1202-monotherapy-and-combined-with-ublituximab/ 2025-01-31T22:27:36+00:00 https://www.tgtherapeutics.com/publications/open-label-safety-study-of-ublituximab-for-the-treatment-of-acute-neuromyelitis-optica-relapses/ 2025-01-31T22:27:55+00:00 https://www.tgtherapeutics.com/publications/silencing-c-myc-translation-as-a-therapeutic-strategy-through-targeting-pi3k-delta-and-ck1-epsilon-in-hematological-malignancies/ 2025-01-31T22:28:16+00:00 https://www.tgtherapeutics.com/publications/tgr-1202-in-combination-with-ibrutinib-in-patients-with-relapsed-or-refractory-cll-or-mcl-preliminary-results-of-a-multicenter-phase-i-ib-study/ 2025-01-31T22:28:42+00:00 https://www.tgtherapeutics.com/publications/preliminary-results-from-a-phase-i-dose-escalation-trial-of-ruxolitinib-and-the-pi3k-delta-inhibitor-tgr-1202-in-myelofibrosis/ 2025-01-31T22:28:57+00:00 https://www.tgtherapeutics.com/publications/combination-of-ublituximab-tgr-1202-and-bendamustine-demonstrates-significant-activity-in-patients-with-advanced-dlbcl-and-follicular-lymphoma/ 2025-01-31T22:29:09+00:00 https://www.tgtherapeutics.com/publications/a-phase-i-trial-of-tgr-1202-a-next-generation-once-daily-pi3k-delta-inhibitor-in-combination-with-brentuximab-vedotin-in-patients-with-relapsed-refractory-hodgkins-lymphoma/ 2025-01-31T22:29:22+00:00 https://www.tgtherapeutics.com/publications/silencing-cmyc-translation-as-a-therapeutic-strategy-through-targeting-pi3k-delta-and-ck1-epsilon-in-hematological-malignancies/ 2025-01-31T22:29:47+00:00 https://www.tgtherapeutics.com/publications/modulation-of-t-cell-compartment-in-a-preclinical-cll-murine-model-by-a-selective-pi3k-delta-inhibitor-tgr-1202/ 2025-01-31T22:30:03+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tg-1101-a-novel-glycoengineered-anti-cd20-antibody-in-combination-with-ibrutinib-is-safe-and-highly-active-in-patients-with-relapsed-and-or-refractory-chronic-lymphocytic-leukaemia-re/ 2025-01-31T22:30:28+00:00 https://www.tgtherapeutics.com/publications/ki-intolerance-study-a-phase-2-study-to-assess-the-safety-and-efficacy-of-tgr-1202-in-pts-with-chronic-lymphocytic-leukemia-cll-who-are-intolerant-to-prior-btk-or-pi3k-delta-inhibitor-therapy/ 2025-01-31T22:30:46+00:00 https://www.tgtherapeutics.com/publications/preliminary-results-of-phase-2-multicenter-study-of-ublituximab-utx-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-patients-with-relapsing-forms-of-multiple-sclerosis-rms-demonst-2/ 2025-01-31T22:31:05+00:00 https://www.tgtherapeutics.com/publications/preclinical-characterization-of-a-fully-human-lgg1-anti-pd-l1-mab-ck-301/ 2025-01-31T22:31:17+00:00 https://www.tgtherapeutics.com/publications/rapid-and-robust-b-cell-depletion-in-preliminary-results-of-a-phase-2-study-of-ublituximab-novel-glycoengineered-anti-cd20-mab-rms-patients/ 2025-01-31T22:31:41+00:00 https://www.tgtherapeutics.com/publications/tgr-1202-a-novel-pi3k-delta-inhibitor-that-differentially-regulates-t-cells-in-cll/ 2025-01-31T22:31:54+00:00 https://www.tgtherapeutics.com/publications/tgr-1202-in-combination-with-ibrutinib-in-patients-with-relapsed-or-refractory-cll-updated-results-of-a-multicenter-phase-i-ib-study/ 2025-01-31T22:32:10+00:00 https://www.tgtherapeutics.com/publications/tolerability-and-activity-of-chemo-free-triplet-combination-of-umbralisib-tgr-1202-ublituximab-and-ibrutinib-in-patients-with-advanced-cll-and-nhl-2/ 2025-01-31T22:32:38+00:00 https://www.tgtherapeutics.com/publications/rapid-and-robust-b-cell-depletion-in-preliminary-results-of-phase-2-multicenter-study-of-ublituximab-utx-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-patients-with-relapsing-forms/ 2025-01-31T22:33:04+00:00 https://www.tgtherapeutics.com/publications/ublituximab-and-ibrutinib-for-previously-treated-genetically-high-risk-chronic-lymphocytic-leukemia-results-of-the-genuine-phase-3-study/ 2025-01-31T22:33:23+00:00 https://www.tgtherapeutics.com/publications/combination-of-tgr-1202-ublituximab-and-bendamustine-is-safe-and-highly-active-in-patients-with-advanced-dlbcl-and-follicular-lymphoma-2/ 2025-01-31T22:33:38+00:00 https://www.tgtherapeutics.com/publications/updated-results-of-a-multicenter-phase-i-ib-study-of-umbralisib-tgr-1202-in-combination-with-ibrutinib-in-patients-with-relapsed-or-refractory-mcl-or-cll/ 2025-01-31T22:34:12+00:00 https://www.tgtherapeutics.com/publications/tolerability-and-activity-of-chemo-free-triplet-combination-of-tgr-1202-ublituximab-and-ibrutinib-in-patients-with-advanced-cll-and-nhl/ 2025-01-31T22:34:25+00:00 https://www.tgtherapeutics.com/publications/ublituximab-and-ibrutinib-for-previously-treated-genetically-high-risk-chronic-lymphocytic-leukemia-results-of-the-genuine-phase-3-study-2/ 2025-01-31T22:34:37+00:00 https://www.tgtherapeutics.com/publications/placebo-controlled-phase-2a-multicenter-study-of-ublituximab-utx-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-patients-with-relapsing-forms-of-multiple-sclerosis-rms-6-months/ 2025-01-31T22:34:56+00:00 https://www.tgtherapeutics.com/publications/patient-characteristics-safety-and-preliminary-results-of-a-placebo-controlled-phase-2a-multicenter-study-of-ublituximab-utx-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-patie/ 2025-01-31T22:35:08+00:00 https://www.tgtherapeutics.com/publications/preliminary-results-of-phase-2-multicenter-study-of-ublituximab-utx-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-patients-with-relapsing-forms-of-multiple-sclerosis-rms-demonst/ 2025-01-31T22:35:20+00:00 https://www.tgtherapeutics.com/publications/ki-intolerance-study-a-phase-2-study-to-assess-the-safety-and-efficacy-of-umbralisib-tgr-1202-in-patients-with-chronic-lymphocytic-leukemia-cll-who-are-intolerant-to-prior-btk-or-pi3k-delta-inhib/ 2025-01-31T22:35:42+00:00 https://www.tgtherapeutics.com/publications/an-integrated-safety-analysis-of-the-next-generation-pi3k-delta-inhibitor-umbralisib-tgr-1202-in-patients-with-relapsed-refractory-lymphoid-malignancies/ 2025-01-31T22:35:55+00:00 https://www.tgtherapeutics.com/publications/pi3k-delta-inhibitors-induce-primary-monocyte-cytotoxicity-but-do-not-alter-monocyte-differentiation/ 2025-01-31T22:36:13+00:00 https://www.tgtherapeutics.com/publications/phase-i-ii-study-of-pembrolizumab-in-combination-with-ublituximab-tg-1101-and-umbralisib-tgr-1202-in-patients-with-relapsed-refractory-cll/ 2025-01-31T22:36:28+00:00 https://www.tgtherapeutics.com/publications/umbralisib-tgr-1202-as-a-novel-dual-pi3k-ck1-inhibitor-has-a-unique-therapeutic-role-in-silencing-oncogenes-in-aggressive-lymphomas/ 2025-01-31T22:36:41+00:00 https://www.tgtherapeutics.com/publications/differential-regulation-of-t-cells-by-pi3k-delta-inhibitors-in-a-cll-murine-model/ 2025-01-31T22:36:54+00:00 https://www.tgtherapeutics.com/publications/umbralisib-a-novel-pi3k%ce%b4-and-casein-kinase-1%ce%b5-inhibitor-in-relapsed-or-refractory-chronic-lymphocytic-leukaemia-and-lymphoma-an-open-label-phase-1-dose-escalation-first-in-human-study/ 2025-01-31T22:37:13+00:00 https://www.tgtherapeutics.com/publications/6-month-results-of-a-phase-2a-multicenter-study-of-ublituximab-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-in-relapsing-multiple-sclerosis/ 2025-01-31T22:37:26+00:00 https://www.tgtherapeutics.com/publications/final-mri-results-at-6-months-from-a-phase-2-multicenter-study-of-ublituximab-a-novel-glyocoengineered-anti-cd20-monoclonal-antibody-mab-in-patients-with-relapsing-forms-of-multiple-sclerosis-rms/ 2025-01-31T22:37:43+00:00 https://www.tgtherapeutics.com/publications/tg-1601-is-a-novel-bet-inhibitor-with-strong-binding-affinity-and-long-lasting-effect-in-pre-clinical-models/ 2025-01-31T22:37:54+00:00 https://www.tgtherapeutics.com/publications/phase-2-multicenter-study-results-of-ublituximab-a-novel-glycoengineered-anticd20-monoclonal-antibody-mab-in-patients-with-relapsing-multiple-sclerosis-rms/ 2025-01-31T22:38:13+00:00 https://www.tgtherapeutics.com/publications/resurrecting-response-to-ruxolitinib-a-phase-i-study-of-ruxolitinib-and-umbralisib-tgr-1202-in-ruxolitinib-experienced-myelofibrosis/ 2025-01-31T22:38:27+00:00 https://www.tgtherapeutics.com/publications/a-phase-2-study-to-assess-the-safety-and-efficacy-of-umbralisib-tgr-1202-in-patients-with-chronic-lymphocytic-leukemia-cll-who-are-intolerant-to-prior-btk-or-pi3k-delta-inhibitor-therapy/ 2025-01-31T22:38:40+00:00 https://www.tgtherapeutics.com/publications/long-term-integrated-safety-analysis-of-umbralisib-tgr-1202-a-pi3k-ck1-inhibitor-with-a-differentiated-safety-profile-in-patients-with-relapsed-refractory-lymphoid-malignancies/ 2025-01-31T22:38:58+00:00 https://www.tgtherapeutics.com/publications/tg-1701-is-a-novel-orally-available-and-covalently-bound-btk-inhibitor/ 2025-01-31T22:39:09+00:00 https://www.tgtherapeutics.com/publications/final-results-of-a-placebo-controlled-phase-2-multicenter-study-of-ublituximab-utx-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-patients-with-relapsing-forms-of-multiple-scleros/ 2025-01-31T22:39:27+00:00 https://www.tgtherapeutics.com/publications/umbralisib-in-combination-with-ibrutinib-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia-or-mantle-cell-lymphoma-a-multicentre-phase-1-1b-study/ 2025-01-31T22:39:47+00:00 https://www.tgtherapeutics.com/publications/phase-i-ii-study-of-umbralisib-tgr-1202-in-combination-with-ublituximab-tg-1101-and-pembrolizumab-in-patients-with-relapsed-refractory-cll-and-richters-transformation-2/ 2025-01-31T22:40:16+00:00 https://www.tgtherapeutics.com/publications/final-results-of-a-phase-2-multicenter-study-of-ublituximab-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-in-patients-with-relapsing-forms-of-multiple-sclerosis-rms/ 2025-01-31T22:40:37+00:00 https://www.tgtherapeutics.com/publications/tolerability-and-activity-of-ublituximab-umbralisib-and-ibrutinib-in-patients-with-chronic-lymphocytic-leukaemia-and-non-hodgkin-lymphoma-a-phase-1-dose-escalation-and-expansion-trial/ 2025-01-31T22:40:50+00:00 https://www.tgtherapeutics.com/publications/open-label-extension-ole-of-a-phase-2-multicenter-study-of-ublituximab-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-patients-with-relapsing-forms-of-multiple-sclerosis-rms/ 2025-01-31T22:41:25+00:00 https://www.tgtherapeutics.com/publications/b-cell-depletion-with-ublituximab-reshapes-the-t-cell-profile-in-multiple-sclerosis-patients/ 2025-01-31T22:41:37+00:00 https://www.tgtherapeutics.com/publications/phase-i-ii-study-of-umbralisib-tgr-1202-in-combination-with-ublituximab-tg-1101-and-pembrolizumab-in-patients-with-relapsed-refractory-cll-and-richters-transformation/ 2025-01-31T22:41:56+00:00 https://www.tgtherapeutics.com/publications/a-phase-2-study-to-assess-the-safety-and-efficacy-of-umbralisib-in-patients-with-chronic-lymphocytic-leukemia-cll-who-are-intolerant-to-prior-btk-or-pi3k-delta-inhibitor-therapy-2/ 2025-01-31T22:42:08+00:00 https://www.tgtherapeutics.com/publications/the-novel-bispecific-cd47-cd19-antibody-tg-1801-potentiates-the-activity-of-ublituximab-umbralisib-u2-drug-combination-in-preclinical-models-of-b-nhl/ 2025-01-31T22:42:19+00:00 https://www.tgtherapeutics.com/publications/open-label-extension-ole-of-phase-2-multicenter-study-of-ublituximab-utx-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-patients-with-relapsing-forms-of-multiple-sclerosis-rms/ 2025-01-31T22:42:51+00:00 https://www.tgtherapeutics.com/publications/phase-i-ii-triple-therapy-study-of-umbralisib-and-ublituximab-u2-combined-with-checkpoint-inhibition-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-cll-and-richters-tra/ 2025-01-31T22:43:09+00:00 https://www.tgtherapeutics.com/publications/long-term-follow-up-results-from-the-phase-2-multicenter-study-of-ublituximab-utx-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-patients-with-relapsing-multiple-sclerosis-rms/ 2025-01-31T22:43:21+00:00 https://www.tgtherapeutics.com/publications/study-design-and-patient-demographics-of-the-ultimate-phase-iii-trials-evaluating-ublituximab-utx-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-patients-with-relapsing-multiple-sc/ 2025-01-31T22:43:33+00:00 https://www.tgtherapeutics.com/publications/ublituximab-and-umbralisib-in-relapsed-refractory-b-cell-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia/ 2025-01-31T22:44:05+00:00 https://www.tgtherapeutics.com/publications/phase-1-study-of-tg-1701-a-selective-irreversible-inhibitor-of-brutons-tyrosine-kinase-btk-in-patients-with-relapsed-refractory-b-cell-malignancies/ 2025-01-31T22:44:21+00:00 https://www.tgtherapeutics.com/publications/a-phase-1-2-study-of-umbralisib-ublituximab-and-venetoclax-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-3/ 2025-01-31T22:44:33+00:00 https://www.tgtherapeutics.com/publications/long-term-follow-up-results-from-the-phase-2-multicenter-study-of-ublituximabutx-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-in-patients-with-relapsing-multiple-sclerosis-rms/ 2025-01-31T22:44:50+00:00 https://www.tgtherapeutics.com/publications/a-phase-2-multicenter-study-of-ublituximab-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-in-patients-with-relapsing-forms-of-multiple-sclerosis/ 2025-01-31T22:45:07+00:00 https://www.tgtherapeutics.com/publications/effect-of-adding-ublituximab-to-ibrutinib-on-pfs-orr-and-mrd-negativity-in-previously-treated-high-risk-chronic-lymphocytic-leukemia-final-results-of-the-genuine-phase-iii-study/ 2025-01-31T22:45:22+00:00 https://www.tgtherapeutics.com/publications/tg-1701-a-novel-irreversible-brutons-kinase-btk-inhibitor-cooperates-with-ublituximab-driven-adcc-and-adcp-in-in-vitro-and-in-vivo-models-of-ibrutinib-resistant-mantle-cell-lymphoma/ 2025-01-31T22:45:39+00:00 https://www.tgtherapeutics.com/publications/long-term-results-of-a-phase-i-ib-study-of-ibrutinib-in-combination-with-umbralisib-in-patients-with-relapsed-refractory-cll-or-mcl/ 2025-01-31T22:45:52+00:00 https://www.tgtherapeutics.com/publications/safety-and-activity-of-the-once-daily-selective-bruton-tyrosine-kinase-btk-inhibitor-tg-1701-in-patients-with-chronic-lymphocytic-leukemia-cll-and-lymphoma/ 2025-01-31T22:46:05+00:00 https://www.tgtherapeutics.com/publications/the-dual-pi3k%ce%b4-ck1%ce%b5-inhibitor-umbralisib-exhibits-unique-immunomodulatory-effects-on-cll-t-cells/ 2025-01-31T22:46:23+00:00 https://www.tgtherapeutics.com/publications/umbralisib-plus-ublituximab-u2-is-superior-to-obinutuzumab-plus-chlorambucil-ochl-in-patients-with-treatment-naive-tn-and-relapsed-refractory-r-r-chronic-lymphocytic-leukemia-cll-results-f-2/ 2025-01-31T22:47:24+00:00 https://www.tgtherapeutics.com/publications/a-phase-1-2-study-of-umbralisib-ublituximab-and-venetoclax-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-2/ 2025-01-31T22:47:51+00:00 https://www.tgtherapeutics.com/publications/umbralisib-a-pi3k%ce%b4-ck1%ce%b5-dual-inhibitor-demonstrates-marked-clinical-activity-in-patients-with-relapsed-or-refractory-indolent-non-hodgkin-lymphoma-results-from-the-phase-2-global-unity-nhl/ 2025-01-31T22:48:04+00:00 https://www.tgtherapeutics.com/publications/phase-3-study-of-umbralisib-combined-with-ublituximab-vs-obinutuzumab-plus-chlorambucil-in-patients-with-chronic-lymphocytic-leukemia-results-from-unity-cll/ 2025-01-31T22:48:16+00:00 https://www.tgtherapeutics.com/publications/video-phase-3-study-of-umbralisib-combined-with-ublituximab-vs-obinutuzumab-plus-chlorambucil-in-patients-with-chronic-lymphocytic-leukemia-results-from-unity-cll/ 2025-01-31T22:48:29+00:00 https://www.tgtherapeutics.com/publications/video-umbralisib-a-pi3k%ce%b4-ck1%ce%b5-dual-inhibitor-demonstrates-marked-clinical-activity-in-patients-with-relapsed-or-refractory-indolent-non-hodgkin-lymphoma-results-from-the-phase-2-global-un/ 2025-01-31T22:48:41+00:00 https://www.tgtherapeutics.com/publications/video-a-phase-1-2-study-of-umbralisib-ublituximab-and-venetoclax-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll/ 2025-01-31T22:48:56+00:00 https://www.tgtherapeutics.com/publications/clinical-activity-of-tg-1701-as-monotherapy-and-in-combination-with-ublituximab-and-umbralisib-u2-in-patients-with-b-cell-malignancies/ 2025-01-31T22:49:13+00:00 https://www.tgtherapeutics.com/publications/video-clinical-activity-of-tg-1701-as-monotherapy-and-in-combination-with-ublituximab-and-umbralisib-u2-in-patients-with-b-cell-malignancies/ 2025-01-31T22:49:27+00:00 https://www.tgtherapeutics.com/publications/phase-2-study-of-the-safety-and-efficacy-of-umbralisib-in-patients-with-cll-who-are-intolerant-to-btk-or-pi3k%ce%b4-inhibitor-therapy/ 2025-01-31T22:49:40+00:00 https://www.tgtherapeutics.com/publications/a-phase-3-randomized-trial-of-ublituximab-plus-ibrutinib-for-patients-with-relapsed-refractory-high-risk-chronic-lymphocytic-leukaemia/ 2025-01-31T22:50:03+00:00 https://www.tgtherapeutics.com/publications/umbralisib-a-dual-pi3k%ce%b4-ck1%ce%b5-inhibitor-in-patients-with-relapsed-refractory-indolent-lymphoma/ 2025-01-31T22:50:19+00:00 https://www.tgtherapeutics.com/publications/efficacy-and-safety-of-ublituximab-vs-teriflunomide-in-patients-with-relapsing-multiple-sclerosis-results-from-two-phase-3-studies-ultimate-i-ultimate-ii-american-academy-of-neurology/ 2025-01-31T22:50:37+00:00 https://www.tgtherapeutics.com/publications/antitumoral-activity-of-the-novel-btk-inhibitor-tg-1701-is-associated-with-disruption-of-ikaros-signaling-and-improvement-of-anti-cd20-therapy-in-b-cell-non-hodgkin-lymphoma/ 2025-01-31T22:50:57+00:00 https://www.tgtherapeutics.com/publications/updated-results-of-the-selective-bruton-tyrosine-kinase-btk-inhibitor-tg-1701-as-monotherapy-and-in-combination-with-ublituximab-and-umbralisib-u2-in-patients-pts-with-b-cell-malignancies/ 2025-01-31T22:51:08+00:00 https://www.tgtherapeutics.com/publications/ublituximab-versus-teriflunomide-in-relapsing-multiple-sclerosis-results-of-the-phase-3-ultimate-i-and-ii-trials/ 2025-01-31T22:51:21+00:00 https://www.tgtherapeutics.com/publications/updated-results-of-the-selective-bruton-tyrosine-kinase-btk-inhibitor-tg-1701-as-monotherapy-and-in-combination-with-ublituximab-and-umbralisib-u2-in-patients-pts-with-b-cell-malignancies-2/ 2025-01-31T22:51:34+00:00 https://www.tgtherapeutics.com/publications/updated-results-of-the-selective-bruton-tyrosine-kinase-btk-inhibitor-tg-1701-as-monotherapy-and-in-combination-with-ublituximab-and-umbralisibu2-in-patients-pts-with-b-cell-malignancies/ 2025-01-31T22:51:46+00:00 https://www.tgtherapeutics.com/publications/video-updated-results-of-the-selective-bruton-tyrosine-kinase-btk-inhibitor-tg-1701-as-monotherapy-and-in-combination-with-ublituximab-and-umbralisib-u2-in-patients-pts-with-b-cell-malignanci/ 2025-01-31T22:52:01+00:00 https://www.tgtherapeutics.com/publications/a-phase-1-2-study-of-umbralisib-ublituximab-and-venetoclax-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll/ 2025-01-31T22:52:44+00:00 https://www.tgtherapeutics.com/publications/tg-1701-a-selective-bruton-tyrosine-kinase-btk-inhibitor-as-monotherapy-and-in-combination-with-ublituximab-and-umbralisib-u2-in-patients-with-chronic-lymphocytic-leukemia/ 2025-01-31T22:53:04+00:00 https://www.tgtherapeutics.com/publications/ublituximab-is-associated-with-significant-improvement-in-the-multiple-sclerosis-functional-composite-msfc-results-from-the-phase-3-ultimate-i-ii-studies/ 2025-01-31T22:53:25+00:00 https://www.tgtherapeutics.com/publications/phase-3-results-of-the-ultimate-i-ii-global-studies-ublituximab-versus-teriflunomide-in-relapsing-multiple-sclerosis/ 2025-01-31T22:53:36+00:00 https://www.tgtherapeutics.com/publications/favorable-outcomes-for-patients-with-co-morbidities-or-concomitant-medications-treated-with-u2-a-retrospective-analysis-of-unity-cll-phase-3-trial/ 2025-01-31T22:53:55+00:00 https://www.tgtherapeutics.com/publications/efficacy-and-safety-of-ublituximab-in-combination-with-umbralisib-u2-in-patients-with-chronic-lymphocytic-leukemia-cll-by-treatment-status-a-sub-analysis-of-the-phase-3-unity-cll-study/ 2025-01-31T22:54:06+00:00 https://www.tgtherapeutics.com/publications/a-phase-2-study-evaluating-the-addition-of-ublituximab-and-umbralisib-u2-to-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-cll-a-minimal-residual-disease-mrd-driven-time-limited-appro/ 2025-01-31T22:54:18+00:00 https://www.tgtherapeutics.com/publications/efficacy-and-safety-of-umbralisib-and-ublituximab-u2-and-u2-plus-bendamustine-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl/ 2025-01-31T22:54:32+00:00 https://www.tgtherapeutics.com/publications/the-combination-of-umbralisib-plus-ublituximab-is-active-in-patients-with-relapsed-or-refractory-marginal-zone-lymphoma-mzl-results-from-the-phase-2-global-unity-nhl-trial/ 2025-01-31T22:54:43+00:00 https://www.tgtherapeutics.com/publications/the-selective-brutons-tyrosine-kinase-btk-inhibitor-tg-1701-as-monotherapy-and-in-combination-with-ublituximab-and-umbralisib-u2-in-patients-with-b-cell-malignancies/ 2025-01-31T22:54:55+00:00 https://www.tgtherapeutics.com/publications/reduction-in-t1-hypointense-lesions-with-ublituximab-vs-teriflunomide-in-the-phase-3-ultimate-i-ii-studies-in-relapsing-multiple-sclerosis/ 2025-01-31T22:55:16+00:00 https://www.tgtherapeutics.com/publications/pharmacodynamics-of-b-cell-depletion-and-pharmacokinetics-of-the-novel-anti-cd20-monoclonal-antibody-ublituximab-in-patients-with-relapsing-multiple-sclerosis/ 2025-01-31T22:55:26+00:00 https://www.tgtherapeutics.com/publications/neutralizing-antibodies-and-antidrug-antibodies-in-the-ublituximab-phase-3-ultimate-i-ii-studies-in-relapsing-multiple-sclerosis/ 2025-01-31T22:55:39+00:00 https://www.tgtherapeutics.com/publications/relapse-rate-and-time-to-first-relapse-were-improved-with-ublituximab-vs-teriflunomide-in-the-phase-3-ultimate-i-and-ultimate-ii-studies-in-patients-with-relapsing-multiple-sclerosis-rms/ 2025-01-31T22:55:56+00:00 https://www.tgtherapeutics.com/publications/disability-improvements-with-ublituximab-in-relapsing-multiple-sclerosis-rms-expanded-disability-status-scale-edss-9-hole-peg-test-9-hpt-and-timed-25-foot-walk-t25fw-evaluations-from-the-ph/ 2025-01-31T22:56:07+00:00 https://www.tgtherapeutics.com/publications/ublituximab-treatment-is-associated-with-a-significant-proportion-of-patients-achieving-no-evidence-of-disease-activity-neda-results-from-the-ultimate-i-and-ultimate-ii-phase-3-studies-of-ublituxim/ 2025-01-31T22:56:18+00:00 https://www.tgtherapeutics.com/publications/infusion-related-reactions-irrs-with-ublituximab-in-patients-with-relapsing-multiple-sclerosis-rms-post-hoc-analyses-from-the-phase-3-ultimate-i-and-ii-studies/ 2025-01-31T22:56:32+00:00 https://www.tgtherapeutics.com/publications/improved-quality-of-life-with-ublituximab-in-the-ultimate-i-and-ii-studies-in-relapsing-multiple-sclerosis/ 2025-01-31T22:56:51+00:00 https://www.tgtherapeutics.com/publications/disability-improvements-with-ublituximab-in-relapsing-multiple-sclerosis-pooled-post-hoc-analyses-of-the-ultimate-i-and-ii-studies/ 2025-01-31T22:57:03+00:00 https://www.tgtherapeutics.com/publications/ublituximab-efficacy-outcomes-in-relapsing-multiple-sclerosis-patient-subgroups-in-the-ultimate-i-and-ii-studies/ 2025-01-31T22:57:14+00:00 https://www.tgtherapeutics.com/publications/improved-cognitive-processing-speed-with-ublituximab-in-patients-with-highly-active-relapsing-multiple-sclerosis/ 2025-01-31T22:57:29+00:00 https://www.tgtherapeutics.com/publications/infusion-related-reactions-with-ublituximab-in-the-phase-3-ultimate-i-and-ii-studies-in-relapsing-multiple-sclerosis/ 2025-01-31T22:57:41+00:00 https://www.tgtherapeutics.com/publications/reduced-disease-progression-with-ublituximab-vs-teriflunomide-in-the-phase-3-ultimate-i-and-ii-studies-in-relapsing-multiple-sclerosis/ 2025-01-31T22:57:54+00:00 https://www.tgtherapeutics.com/publications/ublituximab-versus-teriflunomide-in-relapsing-multiple-sclerosis/ 2025-01-31T22:58:12+00:00 https://www.tgtherapeutics.com/publications/functional-systems-scores-and-expanded-disability-status-scale-score-evaluations-in-the-ultimate-i-and-ii-studies-of-ublituximab-versus-teriflunomide-in-participants-with-relapsing-multiple-sclerosis/ 2025-01-31T22:58:32+00:00 https://www.tgtherapeutics.com/publications/disability-changes-in-the-absence-of-relapse-in-the-phase-3-ultimate-i-and-ii-studies-of-ublituximab-versus-teriflunomide-in-participants-with-relapsing-multiple-sclerosis/ 2025-01-31T22:58:42+00:00 https://www.tgtherapeutics.com/publications/ublituximab-treatment-is-associated-with-a-significant-proportion-of-participants-achieving-neda-4/ 2025-01-31T22:58:55+00:00 https://www.tgtherapeutics.com/publications/disease-outcomes-with-ublituximab-in-treatment-naive-participants-subpopulation-analyses-of-the-phase-3-ultimate-i-and-ii-studies-in-participants-with-relapsing-multiple-sclerosis/ 2025-01-31T22:59:09+00:00 https://www.tgtherapeutics.com/publications/b-cell-depletion-and-return-in-participant-subgroups-of-the-phase-3-ultimate-i-and-ii-studies-of-ublituximab-versus-teriflunomide-in-participants-with-relapsing-multiple-sclerosis/ 2025-01-31T22:59:21+00:00 https://www.tgtherapeutics.com/publications/first-in-human-fih-study-of-the-fully-human-kappa-lambda-cd19-cd47-bispecific-antibody-tg-1801-in-patients-pts-with-bcell-lymphoma/ 2025-01-31T22:59:41+00:00 https://www.tgtherapeutics.com/publications/onset-and-maintenance-of-no-evidence-of-disease-activity-with-ublituximab-analyses-of-the-phase-3-ultimate-i-and-ii-studies-in-participants-with-relapsing-multiple-sclerosis/ 2025-01-31T22:59:59+00:00 https://www.tgtherapeutics.com/publications/early-transient-shift-in-hematologic-parameters-observed-with-ublituximab-in-the-ultimate-i-and-ii-phase-3-studies/ 2025-01-31T23:00:10+00:00 https://www.tgtherapeutics.com/publications/ublituximab-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-mab-demonstrates-enhanced-antibody-dependent-cellular-cytolysis-adcc-relative-to-other-anti-cd20-mabs/ 2025-01-31T23:00:30+00:00 https://www.tgtherapeutics.com/publications/ublituximab-efficacy-in-treatment-naive-participants-with-relapsing-multiple-sclerosis-in-the-phase-3-ultimate-i-and-ii-studies/ 2025-01-31T23:00:43+00:00 https://www.tgtherapeutics.com/publications/disease-outcomes-with-ublituximab-in-participants-with-highly-active-disease-subpopulation-analyses-of-the-phase-3-ultimate-i-and-ii-studies-in-participants-with-relapsing-multiple-sclerosis/ 2025-01-31T23:00:54+00:00 https://www.tgtherapeutics.com/publications/ublituximab-is-associated-with-significant-improvement-in-fatigue-results-from-ultimate-i-and-ii/ 2025-01-31T23:01:10+00:00 https://www.tgtherapeutics.com/publications/ublituximab-reduces-thalamic-volume-loss-and-new-lesion-formation-in-participants-of-the-ultimate-i-ii-phase-3-studies/ 2025-01-31T23:04:13+00:00 https://www.tgtherapeutics.com/publications/long-term-follow-up-of-the-pi3k-delta-inhibitor-tgr-1202-demonstrates-a-differentiated-safety-profile-and-high-response-rates-in-cll-integrated-analysis-of-tgr-1202-monotherapy-and-combined-with-ubli/ 2025-01-31T23:07:58+00:00 https://www.tgtherapeutics.com/publications/a-phase-1-2-trial-of-ublituximab-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-in-patients-with-b-cell-non-hodgkin-lymphoma-or-chronic-lymphocytic-leukaemia-previously-exposed-to-rituximab/ 2025-04-08T15:17:28+00:00 https://www.tgtherapeutics.com/publications/lfb-r603-a-third-generation-monoclonal-anti-cd20-antibody-displays-additive-antitumor-activity-with-antileukemic-chemotherapeutic-agents-in-mouse-xenograft-models/ 2025-09-19T19:40:16+00:00 https://www.tgtherapeutics.com/publications/umbralisib-monotherapy-demonstrates-efficacy-and-safety-in-patients-with-relapsed-refractory-marginal-zone-lymphoma-a-multicenter-open-label-registration-directed-phase-2-study/ 2025-09-22T18:33:15+00:00 https://www.tgtherapeutics.com/publications/the-novel-bispecific-cd47-cd19-antibody-tg-1801-potentiates-the-activity-of-ublituximab-umbralisib-u2-drug-combination-in-preclinical-models-of-b-nhl-2/ 2025-09-22T18:41:56+00:00 https://www.tgtherapeutics.com/publications/umbralisib-monotherapy-demonstrates-efficacy-and-safety-in-patients-with-relapsed-refractory-marginal-zone-lymphoma-a-multicenter-open-label-registration-directed-phase-2-study-2/ 2025-09-22T18:46:15+00:00 https://www.tgtherapeutics.com/publications/umbralisib-plus-ublituximab-u2-is-superior-to-obinutuzumab-plus-chlorambucil-ochl-in-patients-with-treatment-naive-tn-and-relapsed-refractory-r-r-chronic-lymphocytic-leukemia-cll-results-f-3/ 2025-09-30T15:30:14+00:00 https://www.tgtherapeutics.com/publications/phase-i-ii-study-of-umbralisib-tgr-1202-ublituximab-tg-1101-and-pembrolizumab-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-and-richters-transformation-5-year-fo-2/ 2025-09-30T15:34:46+00:00 https://www.tgtherapeutics.com/publications/integrated-safety-analysis-of-umbralisib-a-dual-pi3k%ce%b4-ck1%ce%b5-inhibitor-in-relapsed-refractory-lymphoid-malignancies/ 2025-09-30T15:36:29+00:00 https://www.tgtherapeutics.com/publications/a-phase-1-2-study-of-umbralisib-ublituximab-and-venetoclax-u2-ven-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll/ 2025-09-30T15:37:57+00:00 https://www.tgtherapeutics.com/publications/umbralisib-the-once-daily-dual-inhibitor-of-pi3k%ce%b4-and-casein-kinase-1%ce%b5-demonstrates-clinical-activity-in-patients-with-relapsed-or-refractory-indolent-non-hodgkin-lymphoma-results-from-the/ 2025-09-30T15:39:18+00:00 https://www.tgtherapeutics.com/publications/clinical-activity-of-tg-1701-as-monotherapy-and-in-combination-with-ublituximab-and-umbralisib-u2-in-patients-with-b-cell-malignancies-2/ 2025-09-30T15:40:11+00:00 https://www.tgtherapeutics.com/publications/a-phase-2-study-to-assess-the-safety-and-efficacy-of-umbralisib-in-patients-with-chronic-lymphocytic-leukemia-cll-who-are-intolerant-to-prior-btk-or-pi3k-delta-inhibitor-therapy/ 2025-09-30T15:42:56+00:00 https://www.tgtherapeutics.com/publications/12667/ 2025-09-30T15:59:39+00:00 https://www.tgtherapeutics.com/publications/combination-of-umbralisib-ublituximab-and-bendamustine-is-safe-and-highly-active-in-patients-with-advanced-dlbcl-and-follicular-lymphoma/ 2025-09-30T16:00:54+00:00 https://www.tgtherapeutics.com/publications/tolerability-and-activity-of-chemo-free-triplet-combination-of-umbralisib-tgr-1202-ublituximab-and-ibrutinib-in-patients-with-advanced-cll-and-nhl/ 2025-09-30T16:03:35+00:00 https://www.tgtherapeutics.com/publications/combination-of-tgr-1202-ublituximab-and-bendamustine-is-safe-and-highly-active-in-patients-with-advanced-dlbcl-and-follicular-lymphoma/ 2025-09-30T16:04:30+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tg-1101-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-in-combination-with-ibrutinib-is-highly-active-in-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma-results-o/ 2025-09-30T16:14:09+00:00 https://www.tgtherapeutics.com/publications/a-novel-once-daily-pi3k-delta-inhibitor-demonstrates-clinical-activity-with-a-favorable-differentiated-safety-profile-as-a-single-agent-and-in-combination-with-a-novel-glyocengineered-anti-cd20-mab-2/ 2025-09-30T16:22:01+00:00 https://www.tgtherapeutics.com/publications/ublituximab-tg-1101-a-novel-glycoengineered-anti-cd20-monoclonal-antibody-in-combination-with-ibrutinib-is-highly-active-in-patients-with-relapsed-and-or-refractory-mantle-cell-lymphoma-results-o-2/ 2025-09-30T16:24:21+00:00 https://www.tgtherapeutics.com/publications/a-phase-i-trial-of-tgr-1202-a-next-generation-once-daily-pi3k-delta-inhibitor-in-combination-with-obinutuzumab-plus-chlorambucil-in-patients-with-chronic-lymphocytic-leukemia-2/ 2025-09-30T16:25:04+00:00 https://www.tgtherapeutics.com/publications/real-world-clinical-experience-from-enable-the-first-phase-4-observational-study-for-patients-with-relapsing-multiple-sclerosis-initiating-ublituximab/ 2025-10-01T14:52:38+00:00 https://www.tgtherapeutics.com/publications/long-term-efficacy-and-safety-of-ublituximab-in-relapsing-multiple-sclerosis-results-from-6-years-of-ultimate-i-and-ii-open-label/ 2025-10-01T14:53:11+00:00 https://www.tgtherapeutics.com/publications/retrospective-evaluation-of-infusion-tolerability-ublituximab-real-world-observational-survey-enamor-2/ 2025-10-01T14:54:09+00:00 https://www.tgtherapeutics.com/publications/no-association-between-decreases-in-serum-immunoglobulin-ig-levels-below-lower-limit-of-normal-lln-and-serious-infections-si-with-long-term-ublituximab-ubl-treatment-in-patients-with-relapsing-2/ 2025-10-01T14:54:40+00:00 https://www.tgtherapeutics.com/publications/five-years-of-ublituximab-in-relapsing-multiple-sclerosis-results-from-the-openlabel-extension-of-ultimate-i-and-ii-studies/ 2025-10-01T14:55:19+00:00 https://www.tgtherapeutics.com/publications/safety-and-tolerability-of-30-minute-ublituximab-infusions-updates-from-the-enhance-study-2/ 2025-10-01T14:55:55+00:00 https://www.tgtherapeutics.com/publications/safety-and-tolerability-of-a-modified-dosing-regimen-of-ublituximab-updates-from-the-enhance-study/ 2025-10-01T14:56:52+00:00 https://www.tgtherapeutics.com/publications/no-association-between-decreases-in-serum-immunoglobulin-ig-levels-below-lower-limit-of-normal-lln-and-serious-infections-si-with-long-term-ublituximab-ubl-treatment-in-patients-with-relapsing/ 2025-10-01T14:57:28+00:00 https://www.tgtherapeutics.com/publications/enable-the-first-phase-4-observational-study-for-patients-with-relapsing-ms-treated-with-ublituximab-in-real-world-clinical-settings/ 2025-10-01T14:57:57+00:00 https://www.tgtherapeutics.com/publications/switching-to-ublituximab-from-prior-anti-cd20-monoclonal-antibody-therapy-a-case-report-series/ 2025-10-01T14:58:54+00:00 https://www.tgtherapeutics.com/publications/the-evolution-of-anti-cd20-treatment-for-multiple-sclerosis-optimization-of-antibody-characteristics-and-function/ 2025-10-01T14:59:29+00:00 https://www.tgtherapeutics.com/publications/safety-and-tolerability-of-30-minute-ublituximab-infusions-updates-from-the-enhance-study/ 2025-10-01T15:00:11+00:00 https://www.tgtherapeutics.com/publications/the-design-of-a-study-to-evaluate-fc-biology-and-genetic-diversity-in-multiple-sclerosis/ 2025-10-01T15:00:46+00:00 https://www.tgtherapeutics.com/publications/improvements-in-no-evidence-of-disease-activity-with-ublituximab-vs-teriflunomide-in-the-ultimate-phase-3-studies-in-relapsing-multiple-sclerosis/ 2025-10-01T15:01:18+00:00 https://www.tgtherapeutics.com/publications/comparison-of-multiple-sclerosis-disease-activity-msda-test-results-between-patients-treated-with-ublituximab-and-teriflunomide-in-the-phase-3-ultimate-i-and-ii-studies/ 2025-10-01T15:01:50+00:00 https://www.tgtherapeutics.com/publications/efficacy-and-tolerability-of-ublituximab-after-transitioning-from-a-different-disease-modifying-therapy-updates-from-the-enhance-study/ 2025-10-01T15:03:16+00:00 https://www.tgtherapeutics.com/publications/briumvi-pregnancy-registry-a-prospective-study-of-pregnancy-and-infant-outcomes-in-patients-treated-with-briumvi-ublituximab-xiiy/ 2025-10-01T15:03:45+00:00 https://www.tgtherapeutics.com/publications/a-post-marketing-study-evaluating-the-presence-and-concentration-of-briumviublituximab-xiiy-in-breastmilk-provide/ 2025-10-01T15:04:14+00:00 https://www.tgtherapeutics.com/publications/early-initiation-of-ublituximab-treatment-is-associated-with-improved-disability-outcomes-among-treatment-naive-participants-in-ultimate-i-and-ii/ 2025-10-01T15:04:46+00:00 https://www.tgtherapeutics.com/publications/ublituximab-significantly-reduces-radiological-disease-activity-at-12-weeks-post-hoc-analysis-of-participants-with-highly-active-disease-in-the-ultimate-i-ii-phase-3-studies/ 2025-10-01T15:05:50+00:00 https://www.tgtherapeutics.com/publications/ms-relapse-redefined-distinguishing-true-relapses-from-pseudoexacerbations-in-the-ultimate-i-and-ii-trials-comparing-ublituximab-vs-teriflunomide/ 2025-10-01T15:06:27+00:00 https://www.tgtherapeutics.com/publications/evaluating-the-maintenance-of-efficacy-and-tolerability-of-transitioning-from-iv-anti-cd20-therapy-to-ublituximab-enhance-study-interim-data/ 2025-10-01T15:07:03+00:00 https://www.tgtherapeutics.com/publications/disease-activity-score-and-disease-pathway-scores-measured-using-the-multiple-sclerosis-disease-activity-test-are-significantly-reduced-prior-to-the-week-96-dose-for-patients-treated-with-ublituximab/ 2025-10-01T15:08:08+00:00 https://www.tgtherapeutics.com/publications/ms-relapse-redefined-addressing-the-radiological-pseudoexacerbation-paradox-with-high-efficacy-therapy-in-the-ultimate-i-and-ii-trials/ 2025-10-01T15:09:26+00:00 https://www.tgtherapeutics.com/publications/evaluating-the-maintenance-of-efficacy-and-tolerability-when-transitioning-from-iv-anti-cd20-therapy-to-ublituximab-enhance-study-design-patient-demographics-and-preliminary-data/ 2025-10-01T15:10:15+00:00 https://www.tgtherapeutics.com/publications/tg-therapeutics-reports-positive-interim-data-from-unity-nhl-phase-2b-trial-evaluating-umbralisib-monotherapy-in-patients-with-marginal-zone-lymphoma-at-the-2019-aacr-annual-meeting/ 2025-10-02T19:55:00+00:00 https://www.tgtherapeutics.com/publications/five-years-of-ublituximab-in-relapsing-multiple-sclerosis-results-from-the-open-label-extension-of-ultimate-i-and-ii-studies/ 2025-10-08T18:59:47+00:00 https://www.tgtherapeutics.com/publications/safety-and-tolerability-of-a-modified-ublituximab-dosing-regimen-updates-from-the-enhance-study/ 2026-02-06T14:05:32+00:00 https://www.tgtherapeutics.com/publications/real-world-infusion-experience-with-ublituximab-in-enable-the-phase-4-observational-study/ 2026-02-06T14:05:54+00:00 https://www.tgtherapeutics.com/publications/study-design-of-a-phase-2-ublituximab-dose-confirmation-study-in-children-and-adolescents-with-relapsing-multiple-sclerosis-ultimate-kids-i/ 2026-02-06T14:07:50+00:00 https://www.tgtherapeutics.com/publications/study-design-of-a-phase-3-randomized-double-blind-study-of-ublituximab-versus-fingolimod-in-children-and-adolescents-with-relapsing-multiple-sclerosis-ultimate-kids-ii-2/ 2026-02-17T12:43:27+00:00 https://www.tgtherapeutics.com/publications/five-years-of-ublituximab-in-multiple-sclerosis-ultimate-i-and-ii-open-label-extension-study/ 2026-02-17T15:22:49+00:00 https://www.tgtherapeutics.com/publications/efficacy-of-ublituximab-in-people-with-highly-active-relapsing-multiple-sclerosis/ 2026-03-09T11:27:31+00:00 https://www.tgtherapeutics.com/publications/real-world-clinical-experience-from-enable-the-first-phase-4-observational-study-for-patients-with-relapsing-multiple-sclerosis-initiating-ublituximab-2/ 2026-04-21T22:03:08+00:00 https://www.tgtherapeutics.com/publications/safety-and-tolerability-of-a-modified-ublituximab-dosing-regimen-updates-from-the-enhance-study-2/ 2026-04-21T22:03:57+00:00 https://www.tgtherapeutics.com/publications/retrospective-evaluation-of-infusion-tolerability-ublituximab-real-world-observational-survey-enamor/ 2026-05-13T22:34:59+00:00 https://www.tgtherapeutics.com/publications/real-world-transition-to-ublituximab-from-prior-anti-cd20-treatment-in-the-phase-4-enable-study/ 2026-05-26T11:21:00+00:00 https://www.tgtherapeutics.com/publications/evaluation-of-ublituximab-infusion-tolerability-analysis-of-data-following-the-ultimate-phase-3-studies/ 2026-05-26T11:22:29+00:00 https://www.tgtherapeutics.com/publications/evaluating-the-presence-and-concentration-of-briumvi-ublituximab-xiiy-in-breastmilk-provide-an-interim-report/ 2026-05-26T11:29:05+00:00 https://www.tgtherapeutics.com/publications/ublituximab-significantly-improves-patient-reported-outcomes-results-from-the-phase-4-observational-study-enable/ 2026-05-26T11:45:01+00:00 https://www.tgtherapeutics.com/publications/disease-outcomes-with-ublituximab-in-treatment-naive-participants-subpopulation-analyses-of-the-phase-3-ultimate-i-and-ii-studies-in-participants-with-relapsing-multiple-sclerosis-2/ 2026-06-01T11:26:17+00:00